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Abstract Posaconazole is a second-generation triazole agent
with a potent and broad antifungal activity. In addition to the
oral suspension, a delayed-release tablet and intravenous for-
mulation with improved pharmacokinetic properties have
been introduced recently. Due to the large interindividual
and intraindividual variation in bioavailability and drug-drug
interactions, therapeutic drug monitoring (TDM) is advised to
ensure adequate exposure and improve clinical response for
posaconazole. Here, we highlight and discuss the most recent
findings on pharmacokinetics and pharmacodynamics of
posaconazole in the setting of prophylaxis and treatment of
fungal infections and refer to the challenges associated with
TDM of posaconazole.
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Introduction
Invasive fungal disease (IFD) is associated with substantial
morbidity and mortality [1]. Infections with Candida spp.
are most often observed in hematology-oncology and surgical
patients [1]. Invasive aspergillosis (IA) occurs most frequently
in neutropenic hematology-oncology patients and solid organ
transplant and hematopoietic stem cell transplant patients [1].
Among solid organ transplant patients, lung transplant recip-
ients are particularly at risk for IA [1].
Posaconazole is a second-generation triazole agent with a
potent and broad antifungal in vitro activity against a range of
different fungal pathogens, including Aspergillus spp. and
Candida spp. It is structurally related to itraconazole and in-
hibits lanosterol 14α-demethylase (CYP51), blocking the syn-
thesis of ergosterol resulting in impaired cell membrane stabil-
ity and accumulation of precursors leading to fungistatic or
fungicidal effects [2]. Besides facing the increasing prevalence
of resistant fungi [3•, 4], personalized treatment to increase
efficacy and avoid toxicity is urgently needed. Therapeutic drug
monitoring (TDM), in combination with clinical assessment of
response and determination of minimum fungicidal inhibitory
concentration (MIC), may help to optimize treatment results. In
this review, we present recent findings on pharmacokinetics
and pharmacodynamics of posaconazole in the setting of pro-
phylaxis and treatment of fungal infections. In addition, we
evaluate the effects of these recent findings on TDM of
posaconazole in daily practice. For selected topics, we refer to
earlier published reviews for in-depth discussion.
Pharmacokinetics of (New) Posaconazole Drug
Formulations
Posaconazole is currently available in three formulations. The
oral suspension was introduced in 2005. The pharmacokinetic
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profile of the suspension has been outlined extensively [5, 6].
In short, the use of the posaconazole suspension has been
limited due to satiable absorption and variable bioavailability
necessitating the administration in divided doses three to four
times per day. The bioavailability is also strongly dependent
on the concomitant intake of food, gut motility, and gastric
acidity. The absorption of posaconazole is significantly in-
creased when administered with a (high-fat) meal [7].
Several studies have shown subtherapeutic posaconazole con-
centrations in patients with no or limited food intake or after
administration by nasogastric tube [8–10]. Furthermore, co-
administration of the suspension with a proton pump inhibitor,
H2 antagonist, or metoclopramide resulted in subtherapeutic
posaconazole exposures, due to a reduced absorption second-
ary to a decrease in gastric acid production or increased gut
motility [8–12]. The suspension is therefore not preferable for
patients who use these drugs or are unable to eat. Furthermore,
besides these exceptions, it is difficult to obtain consistent
therapeutic levels in general practice, necessitating frequent
TDM [9•, 13].
Recently, a delayed-release tablet and intravenous formu-
lation have been introduced [14, 15•]. The delayed-release,
gastro-resistant film-coated tablet consists of a pH-sensitive
polymer stabilizer excipient that limits posaconazole release
at low pH in the stomach and releases posaconazole at neutral
pH in the small intestine [16]. Compared to the suspension,
the tablet shows an improved bioavailability in healthy sub-
jects, resulting in an approximately fourfold increase in max-
imum concentration (Cmax) and a threefold increase in the
exposure (expressed as area under the concentration-time
curve (AUC)) under fasted conditions [17]. In contrast to the
suspension, the posaconazole exposure after administration of
the tablet is only moderately affected by food. The
posaconazole exposure increased by 1.5-fold when the tablet
was administeredwith a high-fat meal thanwhen administered
in the fasted state, compared to a fourfold increase in exposure
with the suspension [18]. Under fed conditions, exposure was
approximately 35 % higher for the tablet formulation com-
pared to the suspension [17]. Importantly, exposure for the
tablet does not appear to be markedly affected by drugs that
influence gastric acidity or gut motility [14, 17]. Other advan-
tages of the tablet formulation are the once daily administra-
tion and reduced interpatient variability [19]. Moreover, the
tablet showed linear pharmacokinetics for the tested dosage
range (up to 400 mg) [20]. A limited role may remain for the
oral suspension, for example, in the treatment of patients who
are unable to take tablets, such as patients with dysphagia,
children, or patients with enteral feeding tubes [8], as the tablet
must be swallowed whole (not divided, crushed, or chewed).
For these patients, TDM should be applied to assure adequate
exposure (see also below).
The intravenous formulation has also the advantage of a
once daily administration and is suitable for patients who
cannot tolerate oral medication [15•, 19, 21]. A disadvantage
of the intravenous formulation is the need to administrate via a
central venous catheter and the presence of the solubilizing
excipient sulfobutylether-β-cyclodextrin, which may accu-
mulate in patients with moderate to severe renal impairment
potentially leading to (additional) renal toxicity [22].
Although the volume of distribution appeared to be increased
for the suspension, no clinically relevant differences were ob-
served between the other pharmacokinetic parameters of the
suspension, the tablet, and the intravenous formulation
(Table 1) [23].
With the introduction of the new posaconazole formula-
tions, two additional suitable treatment options can be chosen,
which have significantly improved the pharmacokinetics and




Pharmacokinetics describe the behavior of a drug in a patient’s
body, including absorption, distribution, metabolism, and ex-
cretion, whereas pharmacodynamics describe the biochemical
or pharmacological effect of the drug on the patient’s body or,
in case of infectious diseases, the pathogen [25]. Together,
both parameters represent the time-effect course of a drug after
administration in relation to the biochemical or pharmacolog-
ical effect. For antifungal drugs, the pharmacodynamics are
related to the MIC. Studies in in vitro and in vivo models
indicate that the ratio of the total posaconazole AUC over
24 h over the MIC best represents the pharmacokinetic/
pharmacodynamic index for posaconazole in the treatment
of IA [3•]. AUC/MIC ratios of 167 to 187 were found to be
predictive of successful treatment of Aspergillus spp. [3•].
Similarly, also for Rhizopus oryzea mucormycosis, an AUC/
MIC of >100 has been shown to be sufficient [26]. In practice,
an AUC/MIC ratio of 200 is advised for infections with
Aspergillus spp., corresponding to a Cmin/MIC ratio of 5-8
(Table 2) [23]. For prophylaxis, a total posaconazole AUC/
MIC ratio of at least 94 was recently found to be predictive of
success [27].
Due to the large interindividual and intraindividual varia-
tions in bioavailability and drug-drug interactions, TDM has
been proposed as a tool to ensure adequate exposure and im-
prove clinical response for posaconazole [9•, 28–30•].
Although much debated, clinical studies suggest trough levels
of >0.7 mg/l for prophylaxis and trough levels of >1.0–
1.25 mg/l for treatment of IFD (Fig. 1) [13, 29]. However,
these concentrations were established independently of the
susceptibility of the invading fungal pathogen. For the suspen-
sion, the proposed targets could only be reached by a limited
number of subjects for less sensitive strains of Aspergillus
spp., which are still considered to be susceptible
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(MIC≤0.12 mg/l; Table 2) [3•, 31]. With the introduction of
the tablet and intravenous formulations, these targets can be
reached more easily, making it also possible to even treat
subjects with an intermediate sensitive Aspergillus strains, al-
though high doses are likely to be required. In clinical prac-
tice, the tablet formulation is preferred over the oral suspen-
sion as median posaconazole plasma concentrations increased
from 0.75 to 1.9 mg/l in leukemia patients after switching
from the suspension to the solid formulation. Fortunately,
study participants experienced no additional toxicity after
the switch [32]. Exposure may, however, remain also an issue
for the tablets under more extreme conditions as lower
posaconazole trough levels were observed in patients
weighing ≥90 kg or in patients with a body mass index ≥30
[33]. Patients with diarrhoea also showed lower trough levels
on the tablets [33]. For this group and other patients with
absorption problems, the intravenous formulation may be a
valuable addition.
Posaconazole accumulates in lung, kidney, heart, and liver
tissue, but not in the brain. Brain and plasma concentrations
were approximately equal, suggesting that higher plasma con-
centrations may be required for brain infections [34]. Levels in
cerebrospinal fluid were found to be variable, suggesting that
diffusion of posaconazole into the brain is increased with
meningeal inflammation [35]. Moreover, TDM of
posaconazole may become increasingly important to ensure
adequate exposure and thereby prevent the emergence of
posaconazole-resistant strains [36]. Currently, no
concentration-dependent adverse events or toxicity have been
described for posaconazole [29], although an upper boundary
of 3.75mg/l is suggested for the average posaconazole plasma
concentrations by the EuropeanMedicines Agency [16]. With
the introduction of the new dosage forms, these higher levels
may be reached which could result in toxicity for which TDM
may become relevant as well. Recently, it was shown that 3 %
of patients treated with the tablets have trough levels of
≥3.75 mg/l [37•]. In line with this assumption, increasing the
dose of the intravenous formulation from 200 to 300 mg re-
sulted in an increase in adverse events (diarrhea, mucosal in-
flammation, headache, and rash) [15•]. Moreover, use of the
new tablet and intravenous formulations may result in new
adverse events as was already observed for the intravenous
formation, which showed a high number of infusion reactions
after peripheral administration [21]. Collectively, these
Table 1 Pharmacokinetic parameters for posaconazole oral suspension, delayed-release tablet, and IV solution in healthy volunteers
Formulation




200 mg four times a day, 400 mg twice
daily in combination with food
Loading dose 300 mg twice daily
on day 1 followed by 300 mg
once daily
Loading dose 300 mg twice daily on day 1
followed by 300 mg once daily
- Oropharyngeal candiasis 200 mg loading dose on day 1, then
100 mg once daily for 13 days in
combination with food
N/A N/A
- Prophylaxis of IFD 200 mg thrice daily in combination
with food
Loading dose 300 mg twice daily
of day 1 followed by 300 mg
once daily
Loading dose 300 mg twice daily of day 1
followed by 300 mg once daily
VD 1774 L 394 (294–583) L 261 L
Tmax 3 h 4–5 h 90 min (end of infusion)
Protein binding 98 % 98 % 98 %
t1/2 35 (20–66) h 29 (26–31) h 27 h
Elimination (percent of
radiolabelled dose)
Feces (77 %) Feces (77 %) Feces (77 %)
Renal (14 %) Renal (14 %) Renal (14 %)
Time to reach steady state 7–10 days 6 days 6 days
Food-drug interaction Increased Cmax (330 %) and AUC
(360 %) in combination with a
high-fat meal
Increased Cmax (51 %) and AUC
(16 %) in combination with a
high-fat meal
N/A
Drug-drug interactions Drugs affecting gut motility, gastric








IFD invasive fungal disease, VD volume of distribution, Tmax time until the maximum serum concentration, t1/2 half-life, N/A not applicable
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findings indicate an essential role for TDM in the treatment of
invasive fungal infections with posaconazole. TDM can be
further refined with MIC measurements. For empirical treat-
ment and pre-emptive of IFD, we suggest target trough levels
of 1.8 mg/l to cover all sensitive strains. For prophylaxis, a
target trough level of 0.9 mg/l can be suggested based on
AUC/MIC ratios (Table 2), although a trough level of
>0.5 mg/l was recently found to be effective in hematology
patients treated with posaconazole tablets [37•]. For the new
tablet and intravenous formulations, TDM should be applied
in particular in the treatment of IFD as trough levels of
≥1.8 mg/l are expected not be reached in approximately
20 % of patients [38]. For use of these formulations in pro-
phylaxis, TDM should only be performed in exceptional cases
as target levels are expected to be reached in almost all the
patients (Fig. 1) [26]. Use of the posaconazole suspension
should be restricted to a minimum and should always be as-
sociated with TDM. Clinical studies are warranted and cur-
rently ongoing to establish and increase the level of evidence
for the use of TDM, especially for the tablet and intravenous
formulations [39 •].
Alternative Sampling Procedures for TDM
In hospitalized patients, TDM of posaconazole can easily be
performed in serum or plasma. For outpatient monitoring,
sampling may be more problematic. Alternatively, sampling
for posaconazole has been performed using the new dried
blood spot (DBS) technique [40•, 41]. Studies are ongoing
to validate this sampling method in children [42]. With DBS
sampling, blood is obtained using a finger prick instead of a
venous blood sample. After receiving an instruction in DBS
sampling, patients can obtain the DBS samples themselves at
home and sent them by mail to the laboratory for analysis.
Besides the less invasive sampling procedure, DBS analysis
has the advantage of a smaller sampling volume, simpler stor-
age, and transfer of samples at room temperature, without
biohazard risks during the shipment. One study evaluated
Table 2 Possibility of obtaining a therapeutic exposure in the treatment
of invasive aspergillosis for the different posaconazole formulations. Data
represent values calculated for an AUC/MIC ratio of 200. Due to the
linear pharmacokinetics, values can be divided by two for an AUC/




















































































MIC minimum inhibitory concentration, EUCAST EUropean Committee on Antifungal Susceptibility Testing, AUC area under the concentration time
curve, Cmin trough concentration, S susceptible, I intermediate, R resistant
a For MIC values of 0.25 mg/l, AUC/MIC ratios cannot be reached with the standard dose as the registered dose for intravenous use is 300 mg, whereas
the registered dose for the tablets is 400 mg [23]
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the patients’ opinions of the samplingmethod and showed that
patients were satisfied with DBS sampling, and most patients
preferred DBS over venous blood sampling [40 •]. With DBS
analysis, the possibilities of TDM for posaconazole can be
extended to patients at home and to hospitals without a
bioanalytical infrastructure [40 •, 43].
TDM of Posaconazole in the Treatment of IA
Although posaconazole is similar to voriconazole in its activ-
ity against Aspergillus species, use of posaconazole is pre-
served for salvage therapy in patients who are refractory or
intolerant to voriconazole [36, 44, 45]. In case of voriconazole
treatment failure, a switch of antifungal drug class is generally
recommended [44]. Nevertheless, compared with
amphotericin B, itraconazole, voriconazole, or echinocandins,
posaconazole is associated with higher response rates [46].
The efficacy and safety of the posaconazole oral suspension,
which was the only available formulation at that moment, as
monotherapy was investigated in patients with IA who were
refractory or intolerant to conventional antifungal therapy and
was found both save and effective (40–70 % of patients) as
salvage treatment for patients which had previously been
treated with another triazole [44, 46]. Given these results
and its spectrum of activity, posaconazole may be an effective
primary agent for the treatment of IA as well [45]. However,
the place of posaconazole as first-line treatment should be
tested in a randomized, controlled trial comparing the intrave-
nous and tablet formulations against the current standard ther-
apy (voriconazole with TDM), before recommendation as ini-
tial therapy [45, 46]. This study is currently ongoing [47].
Azole resistance is an emerging problem for Aspergillus
species [3•, 4]. The majority of reports concern Aspergillus
fumigatus, although azole resistance has been reported spo-
radically in other species as well [3•]. Azole-resistant
A. fumigatus isolates have been reported in several countries
around the world, and clinical failures have been attributed to
microbiological resistance [4]. A wide range of mutations in
A. fumigatus have been described conferring azole resistance
commonly involving modifications in the CYP51 gene [3•, 4,
48], the target of antifungal azoles. Acquired resistance may
be developed in patients with chronic cavitating aspergillosis
treated after long-term azole exposure, when a susceptible
isolate obtains the ability to resist the activity of the antifungal
agent [3•, 36, 49]. In addition, increasing agricultural use of
azole compounds over many years is held responsible for the
environmental contamination (acquired resistance), leading to
primary resistant isolates in azole-naive patients [3•, 36]. As
Fig. 1 Therapeutic drug monitoring (TDM) of posaconazole. TDM is
recommended after 7 days of treatment for posaconazole in case of the
salvage treatment of invasive fungal infections, interacting drugs (P-gp
inhibitors), of use of the posaconazole oral suspension and in case of
specific clinical circumstances. In case of salvage treatment, TDM is
also required when a pathogen with reduced susceptibility (>0.12 mg/l)
to posaconazole is isolated or when the pathogen is localized at a difficult
to reach site. If the trough level is above 0.7 (0.9)mg/l (AUC/MIC> 100)
for prophylaxis or above 1.25 (1.8)mg/l (AUC/MIC> 200) for salvage
treatment, the dose should be maintained. In case of a trough level below
these target concentrations, effort should be done to increase the
concentration to target levels. IFD invasive fungal disease, MIC
minimum fungicidal inhibitory concentration, and P-gp P-glycoprotein
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long-term therapy of aspergillosis is required in most individ-
uals, and the azoles are the only clinically available agents that
can be administered orally, the development of azole resis-
tance in A. fumigatus is worrisome [4]. If a role for the azoles
remains in the management of azole-resistant aspergillosis,
optimizing drug exposure is critical to increase the probability
of treatment success [3•]. In this context, measuring MIC
values to the azole compounds is crucial to increase the clin-
ical response [3•]. Seyedmousavi et al. proposed break points
of 0.25 to 0.5 mg/l for posaconazole, which are higher than the
EUCAST break points for Aspergillus spp. [3•, 31, 50].
Reduced susceptibility to azoles has significant impact on
the ability to achieve the pharmacodynamic target, and some-
times, targets can only be achieved at the cost of increased
toxicity. Posaconazole exposure (estimated by the AUC) cor-
relates linearly with the dose; thus, a higher dose of the azole is
required to achieve similar efficacy when azole-resistant
strains are present (Table 2) [3•]. With the conventional sus-
pension and dosing of 200 mg four times a day, sufficient
exposures may be difficult to attain. However, such levels
may be obtained with the new posaconazole delayed-release
tablets (Table 2). A case report of a patient with a cerebral
IA which was successfully treated with the tablet formula-
tion has been recently published [51]. The patient has
been treated for a brain abscess with voriconazole for
1 year, but MRI imaging showed a new frontal epidural
fluid collection. It was assumed that susceptibility to
voriconazole was reduced, and therefore, the patient was
switched to posaconazole tablets, 300 mg twice daily. The
trough level after 2 weeks of treatment was 5.3 mg/l. The
dose was reduced to 300 mg once daily, leading to a
trough level of 2.0 mg/l [51]. As cultures were negative,
they were unable to determine MICs. The patient
responded well to the posaconazole, and a repeated MRI
of the brain 4 months after posaconazole initiation showed
a significant improvement consistent with the resolving
infection [51].
Clinical effectiveness of posaconazole salvage treatment
has been shown to be dependent on posaconazole plasma
levels in an externally controlled study [13]. Higher plasma
concentrations of posaconazole were associated with greater
response rates. For patients with average plasma concentra-
tions of >1.25 mg/l, clinical effectiveness was increased to
75 % compared to 24–53 % for patients with lower plasma
levels [13]. Importantly, these levels were only reached in
24 % of the patients in this study with the oral suspension
[13]. Moreover, based on the AUC/MIC targets indicated in
Table 2, target trough levels of 1.8 mg/l are suggested, which
can be reached with the new formulations in most but not all
patients, and therefore, TDM is warranted to assure efficacy
(Fig. 1) [30 •]. Unlike the prophylaxis setting [52], no early
target (48 h) levels are currently available to assure adequate
exposure early in treatment.
TDM of Posaconazole in the Setting of Prophylaxis
IFD is associated with a high mortality and is difficult to treat
[1]. Preventing these infections could possibly increase sur-
vival of immunocompromised patients at risk, including pa-
tients with acute leukemia who are especially vulnerable be-
cause of the long period of neutropenia during treatment with
chemotherapy. Antifungal prophylaxis with fluconazole has
been standard of care for patients undergoing intensive
remission-induction chemotherapy or hematopoietic stem cell
transplantation for the last two decades [53]. However, flucon-
azole lacks activity against invasive mold infections, thereby
limiting its possibilities in preventing these infections.
Contrary to this, posaconazole has an extended spectrum of
activity, including filamentous fungi like Aspergillus,
Zygomycetes, and Fusarium species.
Two landmark clinical trials support the use of
posaconazole as prophylaxis against IFD. A randomized
multi-center open-label study by Cornely et al. found that
posaconazole prophylaxis was associated with a significant
reduction in IFD and improved overall survival (16 versus
22 %) compared to itraconazole and fluconazole prophylaxis
in patients with neutropenia secondary to chemotherapy for
acute myelogenous leukemia or the myelodysplastic syn-
drome [54]. Another trial by Ullmann et al. found that
posaconazole was as effective as fluconazole in preventing
IFD. Posaconazole did show significant superiority in
preventing probable or proven aspergillosis. Overall mortality
was similar between the two treatment groups, but death due
to IFD was lower in the posaconazole group (1 versus 4 %)
[55]. Both studies were performed with posaconazole oral
suspension. After the publication of the multi-center trials,
several real-life experiences confirmed the efficacy of
posaconazole prophylaxis with the suspension in the clinical
setting [56–62]. These observational studies have several lim-
itations; they were partly retrospective and some had historical
controls, but all, except one small study [62], showed a sig-
nificant reduction in IFD [56–61, 63, 64]. Most studies did not
show a reduction in all-cause mortality, except two [58, 61].
The combined level of evidence is reason for all international
guidelines to recommend the use of posaconazole as antifun-
gal prophylaxis in the hematopoietic stem cell transplantation
recipients with GvHD and in neutropenic patients with acute
myelogenous leukemia or myelodysplastic syndrome who are
at high risk for IA [65].
Target trough levels of 0.7 mg/l after 7 days of treatment
are currently being advised by guidelines for TDM of
posaconazole prophylaxis. The rationale for this through level
is based on an analysis by the FDA on the pharmacokinetic
data from the studies by Ullmann et al. and Cornely et al. [37•,
54, 55, 66]. Clinical failure was 25 % at this posaconazole
plasma level and did not improve much at higher concentra-
tions [66]. This relatively high number of events could be due
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to a number of aspects, including variation in tissue concen-
trations and variation in exposure due to use of the oral sus-
pension [26, 34]. In addition to the target level of 0.7 mg/l, a
trough level of >0.35 mg/l after 2 days of treatment has been
suggested as predictive for an appropriate trough level after
1 week of treatment with the oral suspension [52].
Approximately 50 % of the patients had serum levels below
the threshold of <0.7 mg/l when using the posaconazole sus-
pension [30•]. For the tablets, 90 % of patients had trough
levels ≥0.7 mg/l and only 5 % had levels <0.5 mg/l [37•]. In
addition, several smaller and retrospective studies have shown
a positive correlation between the posaconazole exposure and
therapeutic efficacy [30•], supporting the use of TDM when
using the oral suspension. Moreover, based on the AUC/MIC
targets indicated in Table 2, we recommend target trough
levels of 0.9 mg/l, which can be reached with the tablet for-
mulation in the majority of patients [26]. In patients treated
with posaconazole for prophylaxis, TDM seems to be of par-
ticular relevance in case of drug-drug interactions, toxicity, or
use of the oral suspension (Fig. 1).
Treatment of Other Fungi with Posaconazole
Although Aspergillus infections are commonly seen in immu-
nocompromised patients, other opportunistic fungal infec-
tions, like mucormycosis, may also occur. Mucormycosis is
a rare fungal infection with a high mortality. Moreover, the
prevalence of this life-threatening fungal infection is increas-
ing, partly because of increasing resistance to voriconazole
[67]. In contrast to the other triazoles, most Mucorales infec-
tions are susceptible to posaconazole. The first-line treatment
of mucormycosis is liposomal amphotericin B, which shows a
good efficacy for the majority of the strains. Posaconazole is
recommended as salvage therapy, and most strains are suscep-
tible for posaconazole, except for Mucor circinelloides. The
survival rates in patients who used posaconazole as salvage
therapy are described in two series and were found to be 62
and 79 % [67, 68]. In one study, random serum posaconazole
trough levels were assayed; however, no relationship with
clinical efficacy was provided [68]. There is limited data on
survival rate and the susceptibility of posaconazole as first-
line treatment for mucormycosis. In addition to antifungal
treatment, surgery is highly recommended [67, 69, 70]. The
main reasons for switching to posaconazole in clinical practice
are treatment failure or toxicity, especially nephrotoxicity with
long-term first-line treatment with amphotericin B, or the need
for oral treatment as a step down for successfully treated pa-
tients [71]. The new formulations of posaconazole have not
been studied in patients with mucormycosis; however, they
have been successfully applied in neutropenic murine models.
Based on the findings in these models, a Monte Carlo simu-
lation was performed, which showed that with the new formu-
lations of posaconazole, the target AUC/MIC was achieved in
almost all the simulated patients (95–97 %) for an MIC up to
0.12 mg/l for Rhizopus oryzae, while with the suspension, the
AUC/MIC target was only achieved for an MIC up to
0.03 mg/l in almost all simulated patients (96–97 %) [26].
Therefore, the new formulation of posaconazole can be a very
promising alternative treatment of mucormycosis.
Pharmacodynamics of posaconazole for R. oryzea were com-
parable to A. fumigatus. Therefore, similar target trough levels
should be pursued, taking theMIC into account (Table 2) [26].
Furthermore, posaconazole exhibits relatively consistent
activity against Scedosporium spp., as well as voriconazole,
although in vitro susceptibility to voriconazole and
posaconazole is highly variable. For instance, Scedosporium
prolificans seems to be resistant for both voriconazole and
posaconazole. Therefore, antifungal susceptibility testing
plays a crucial role in the treatment of Scedosporium infec-
tions. On average, the MIC values for voriconazole are lower
than those for posaconazole [69, 72, 73]. However, the phar-
macokinetics of voriconazole are highly variable in clinical
practice, which results in variable plasma concentrations of
voriconazole as well [74]. In addition, more adverse effects
are observed for voriconazole compared to posaconazole.
Therefore, the posaconazole tablets can have an advantage
over voriconazole for the treatment of posaconazole suscep-
tible Scedosporium infections. Other triazoles and polyenes,
including amphotericin B deoxycholate and lipid
amphotericin B formulations, have no or limited activity
against these pathogens [69, 72]. Other infections that are
commonly seen in immunocompromised patients are infec-
tions caused by Fusarium spp. The optimal treatment strat-
egy is not yet fully established for these infections, because
clinical trials are lacking. Voriconazole is considered first-
line treatment in immunocompromised patients with
Fusarium infections. Posaconazole can be used as salvage
therapy. Other older azoles show reduced activity against
these organisms [73, 75]. The susceptibility against
Fusarium spp. is also highly variable for voriconazole and
posaconazole. In addition, in vitro susceptibility testing
showed that amphotericin B was the most potent antifungal
agent. The meaning of these in vitro findings for clinical
practice are unknown. Therefore, as for Scedosporium infec-
tions, posaconazole should only be prescribed once suscep-
tibility testing has been performed and susceptibility of the
Fusarium strain has been shown [76]. It is not clear whether
for other species similar pharmacokinetic/pharmacodynamic
targets should be achieved as currently determined for
A. fumigatus and R. oryzae. Future studies are therefore
warranted. Unfortunately, no studies have been performed
or are ongoing investigating the role of TDM in these infec-
tions. But in general, it is accepted that higher posaconazole
exposure is needed than required for treatment of IA and
that TDM should be used to optimize treatment of other
fungal infections as well [69].
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Challenges in Posaconazole TDM
Posaconazole has gained a solid position in prophylaxis and
salvage therapy of IFD [77]. Due to the availability of the new
formulations [14, 15•], posaconazole may increasingly being
used as treatment in situations in which voriconazole may not
be adequate due to possible resistance, drug-drug interactions,
or intolerance. Currently, a phase III study is ongoing compar-
ing posaconazole with voriconazole with TDM as first-line
treatment for IA [47]. More information on TDM of
posaconazole is urgently needed. To date, only retrospective
or prospective observational data on the association between
the posaconazole plasma concentration and efficacy is avail-
able [46, 54, 55, 66]. Data from a prospective randomized
controlled trial comparing posaconazole with and without
TDM is currently lacking. Such a trial would be needed to
add TDM of posaconazole to standard care in the setting of
both prophylaxis and treatment. However, a randomized
TDM trial is not likely to be performed in the setting of pro-
phylaxis due to the large sample size and study costs. In ad-
dition, in the setting of salvage treatment, patients’ conditions
and infections are very heterogeneous, making a design with
two comparable arms complicated. More importantly, it may
no longer be ethical to withhold TDM in a salvage setting as
this is standard practice as shown by the participating of a
wide range of laboratories in a proficiency testing program
for antifungal drugs [78]. On the other hand, do we actually
need level A grade evidence to perform TDM? If we consider
TDM a simple tool to assess drug exposure and accept a level
B/C grade of evidence, we could use TDM of posaconazole in
a targeted population of patients experiencing adverse drug
reactions or showing no clinical response to treatment.
Compared to other diagnostic procedures, like imaging with
PET-CT or biomarker monitoring (galactomannan), measur-
ing a drug level is relatively cheap. As antifungal treatment is
very expensive, preventing escalation to combination treat-
ment by determining a blood concentration, TDM can easily
be cost-effective.
These challenges should actually not withhold us
from collecting the evidence to support TDM. Only
the classical randomized control trial approach may not
be the best strategy to collect the evidence. Innovative
trial designs in a setting of frequent fungal infections
may help to collect the evidence for TDM in a salvage
setting. For example, a multi-arm multi-stage (MAMS)
trial design that proved its use in similar complex in-
fectious diseases, like tuberculosis [79], may be useful
for the evaluation of antifungal treatment guided by
TDM. During interim analyses, the arms performing less
than control are dropped and recruitment for that arm is
stopped. Finally, the remaining novel strategy is com-
pared to standard treatment on a relevant clinical
endpoint.
Conclusion
Due to the new formulations, the role of posaconazole in the
treatment of fungal infections is likely to increase. TDM of
posaconazole is therefore likely to expand as well (Fig. 1).
TDM is currently supported by limited results from several
prospective cohort studies. In a salvage setting, TDM of
posaconazole can be considered as standard of care. To in-
crease the level of evidence to support TDM in other situa-
tions, innovative trial designs have to be employed to make
prospective randomized controlled studies feasible. Moreover,
studies are warranted on early (12–48 h) target levels for the
new dosage forms to assure adequate posaconazole exposure
in fragile patients.
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